Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614702 | 0.81 | DGAT1 (0.34) | F2RL1 | |
| SCHEMBL4015092 | 0.76 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL31222394 | 0.76 | HTT (0.35) | F2RL1 | |
| SCHEMBL14972966 | 0.76 | LMNA (0.40) | — | |
| SCHEMBL30950092 | 0.75 | F2RL1 (0.33) | F2RL1 | |
| SCHEMBL30950122 | 0.74 | F2RL1 (0.33) | F2RL1 | |
| SCHEMBL29232852 | 0.74 | UCHL1 (0.39) | — | |
| SCHEMBL3500142 | 0.73 | DGAT1 (0.32) | F2RL1 | |
| SCHEMBL29514122 | 0.73 | MAPT (0.36) | F2RL1 | |
| SCHEMBL26720199 | 0.73 | MAPT (0.36) | F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2403857-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | F2RL1 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.